Bicocca Open Archive

Logo unimib boa

De Sanctis, R., Bruzzi, P., Zambelli, A. (2024). Unlocking methodological insights on oncology efficacy endpoints: from statistical to clinical and vice versa. Letter to the editor regarding ‘Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3’ by M. P. Goetz et al. ANNALS OF ONCOLOGY, 35(12 (December 2024)), 1201-1202 [10.1016/j.annonc.2024.08.2345].

Unlocking methodological insights on oncology efficacy endpoints: from statistical to clinical and vice versa. Letter to the editor regarding ‘Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3’ by M. P. Goetz et al

Zambelli A.
2024
Lettera in rivista
Breast Cancer; Anticarcinogen; Endocrine Therapy
English
3-set-2024
2024
35
12 (December 2024)
1201
1202
none
De Sanctis, R., Bruzzi, P., Zambelli, A. (2024). Unlocking methodological insights on oncology efficacy endpoints: from statistical to clinical and vice versa. Letter to the editor regarding ‘Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3’ by M. P. Goetz et al. ANNALS OF ONCOLOGY, 35(12 (December 2024)), 1201-1202 [10.1016/j.annonc.2024.08.2345].
01 - Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/526994
Citazioni
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 0
Social impact